Sugi Predict

Sugi Predict / Compounds / SCHEMBL10115263

SCHEMBL10115263

SCHEMBL10115263

CC(=O)N1CCN(c2ccc(NC(=O)CCCCNS(=O)(=O)C(C)C)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.54
▸ KMT2A Q03164 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ MAPK1 P28482 4/20 0.53
▸ KDM4E B2RXH2 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ HTR1A P08908 1/20 0.51
▸ GAA P10253 4/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ ALOX12 P18054 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10113695 0.89 MAPT (0.55) MAPTKMT2AMAPK1KDM4ESMN1; SMN2
SCHEMBL10113693 0.89 KDM4E (0.54) MAPTMAPK1KDM4ESMN1; SMN2HTR1A
SCHEMBL10113690 0.89 GAA (0.59) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL10113674 0.88 SMN1; SMN2 (0.59) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL10113669 0.87 ALDH1A1 (0.59) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL10115256 0.86 KDM4E (0.50) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL11935750 0.86 MAPT (0.54) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL10115361 0.86 KDM4E (0.48) MAPTKMT2AMEN1MAPK1KDM4E
SCHEMBL10113712 0.85 SMN1; SMN2 (0.56) MAPTKMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL10115024 0.85 MAPT (0.54) MAPTKMT2AMEN1MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MAPT 3602/4885KMT2A 2912/4885MEN1 2876/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3367/4885KMT2A 2768/4885MEN1 2932/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MAPT 3683/4885KMT2A 2953/4885MEN1 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.